Key result
Pediatric MIS-C and COVID-19 vaccine myocarditis sera show no specific anticardiac antibody binding vs controls.
Why the study?
Cardiac dysfunction and myocarditis are serious complications of MIS-C and SARS-CoV-2 vaccines, making understanding the role of autoantibodies essential to guide management and vaccination strategies.
Do sera from patients with MIS-C or COVID-19 vaccine-induced myocarditis contain anticardiac IgG, IgM, or IgA autoantibodies that bind human myocardial tissue compared with healthy controls?
Observational (n=48)
Yes
Do sera from patients with MIS-C or COVID-19 vaccine-induced myocarditis contain anticardiac IgG, IgM, or IgA autoantibodies that bind human myocardial tissue compared with healthy controls?
This study found no evidence of serum autoantibodies directly binding to human cardiac tissue in patients with MIS-C or COVID-19 vaccine-induced myocarditis, indicating that direct anticardiac antibody-mediated injury is unlikely to drive cardiac pathology in these conditions.
Answers are grounded in this paper and cite their sources.
Does not support direct anticardiac autoantibody-mediated injury in MIS-C or vaccine myocarditis; hypothesis-generating for alternative mechanisms.
Importance: Cardiac dysfunction and myocarditis have emerged as serious complications of multisystem inflammatory syndrome in children (MIS-C) and vaccines against SARS-CoV-2. Understanding the role of autoantibodies in these conditions is essential for guiding MIS-C management and vaccination strategies in children. Objective: To investigate the presence of anticardiac autoantibodies in MIS-C or COVID-19 vaccine-induced myocarditis. Design, Setting, and Participants: This diagnostic study included children with acute MIS-C or acute vaccine myocarditis, adults with myocarditis or inflammatory cardiomyopathy, healthy children prior to the COVID-19 pandemic, and healthy COVID-19 vaccinated adults. Participants were recruited into research studies in the US, United Kingdom, and Austria starting January 2021. Immunoglobulin G (IgG), IgM, and IgA anticardiac autoantibodies were identified with immunofluorescence staining of left ventricular myocardial tissue from 2 human donors treated with sera from patients and controls. Secondary antibodies were fluorescein isothiocyanate-conjugated antihuman IgG, IgM, and IgA. Images were taken for detection of specific IgG, IgM, and IgA deposits and measurement of fluorescein isothiocyanate fluorescence intensity. Data were analyzed through March 10, 2023. Main Outcomes and Measures: IgG, IgM and IgA antibody binding to cardiac tissue. Results: By cohort, there were a total of 10 children with MIS-C (median [IQR] age, 10 [13-14] years; 6 male), 10 with vaccine myocarditis (median age, 15 [14-16] years; 10 male), 8 adults with myocarditis or inflammatory cardiomyopathy (median age, 55 [46-63] years; 6 male), 10 healthy pediatric controls (median age, 8 [13-14] years; 5 male), and 10 healthy vaccinated adults (all older than 21 years, 5 male). No antibody binding above background was observed in human cardiac tissue treated with sera from pediatric patients with MIS-C or vaccine myocarditis. One of the 8 adult patients with myocarditis or cardiomyopathy had positive IgG staining with raised fluorescence intensity (median [IQR] intensity, 11 060 [10 223-11 858] AU). There were no significant differences in median fluorescence intensity in all other patient cohorts compared with controls for IgG (MIS-C, 6033 [5834-6756] AU; vaccine myocarditis, 6392 [5710-6836] AU; adult myocarditis or inflammatory cardiomyopathy, 5688 [5277-5990] AU; healthy pediatric controls, 6235 [5924-6708] AU; healthy vaccinated adults, 7000 [6423-7739] AU), IgM (MIS-C, 3354 [3110-4043] AU; vaccine myocarditis, 3843 [3288-4748] AU; healthy pediatric controls, 3436 [3313-4237] AU; healthy vaccinated adults, 3543 [2997-4607] AU) and IgA (MIS-C, 3559 [2788-4466] AU; vaccine myocarditis, 4389 [2393-4780] AU; healthy pediatric controls, 3436 [2425-4077] AU; healthy vaccinated adults, 4561 [3164-6309] AU). Conclusions and Relevance: This etiological diagnostic study found no evidence of antibodies from MIS-C and COVID-19 vaccine myocarditis serum binding cardiac tissue, suggesting that the cardiac pathology in both conditions is unlikely to be driven by direct anticardiac antibody-mediated mechanisms.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2023) conducted an observational in Multisystem inflammatory syndrome in children (MIS-C) and COVID-19 vaccination-induced myocarditis (n=48). Sera from patients with MIS-C or COVID-19 vaccine-induced myocarditis vs. Sera from healthy prepandemic pediatric controls, healthy COVID-19 vaccinated adults, and adults with myocarditis or inflammatory cardiomyopathy was evaluated on Presence of specific IgG, IgM, and IgA autoantibody binding and fluorescence intensity on human left ventricular myocardial tissue (p=>0.05). Sera from children with MIS-C and COVID-19 vaccine myocarditis showed 0% specific anticardiac IgG, IgM, or IgA binding and no difference in fluorescence intensity vs controls.
Synapse has enriched 10 related papers. Consider them for comparative context: